Martin Dietrich, MD, PhDMedical Oncologist
Please join us to learn about an FDA-approved first-line monotherapy option in advanced NSCLC.
This program will review:
*Historical clinical trial eligibility considerations in advanced NSCLC
*The design of one of the largest clinical trials in advanced NSCLC
*Clinical evidence for a monotherapy option, approved for use in certain patients with advanced NSCLC
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, this program is limited to U.S. Healthcare Professionals and persons with bona fide professional interest in the information presented. No CME credits are offered for attendance of this presentation. This program is sponsored by Regeneron and Sanofi Genzyme.